While it is imperative to maintain physiologic levels of SCGB1A1 in the lung milieu for an optimal SteadyState respiration, we speculate that a lung locale overexpression of Scgb1a1 via gene therapy or an airway delivery of recombinant protein might be helpful in curbing lung inflammation and cytokine surge in the management of COVID-19 and other inflammatory lung diseases. This evidence concerns the gene SCGB1A1 and COVID-19.